Paclitaxel drug-eluting stents in peripheral arterial disease: OHTAC recommendation
Health Quality Ontario
Record ID 32016000196
English
Authors' recommendations:
OHTAC accepted the findings of the clinical evidence review conducted by HQO. OHTAC also accepted the findings of the budget impact analysis, but noted that the use of the paclitaxel drug-eluting stent would be cost-saving at current prices only if it did indeed substantially reduce the risk for future revascularization procedures.
OHTAC reached a consensus that the clinically meaningful comparison would be one between the paclitaxel drug-eluting stent and the bare metal stent. Given that such a trial is underway, and given that there are other options available for the treatment of peripheral arterial disease, OHTAC decided to recommend against publicly funding paclitaxel drug-eluting stents for the treatment of above-the-knee peripheral arterial disease.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/recommendation-drug-eluting-stent-en-1511.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Peripheral Arterial Disease
- Drug-Eluting Stents
- Paclitaxel
- Sirolimus
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.